Atopic eczema

This early study tests baricitinib, a drug already approved for other immune conditions, in 20 people with Job syndrome who also have lupus-like disease or eczema. Participants take the pill daily for 6 months. The main goal is to see if it is safe and tolerable, while also check…

This early-stage trial is testing whether a gel containing beneficial bacteria (Staphylococcus hominis A9) can safely control eczema flares. About 86 adults and children aged 6 and older will apply the gel or a placebo twice daily for 14 weeks, along with a short course of steroi…

This study tests an injectable drug called amlitelimab for people aged 12 and older with moderate-to-severe eczema that hasn't improved with other treatments. Participants will also use standard steroid creams. The goal is to see if the drug can clear or nearly clear the skin com…

This study is for people with moderate-to-severe eczema who have already completed a previous APG777 trial. It aims to see if APG777 is safe and works well over a longer period. Participants will receive injections of the drug every 12 or 24 weeks and be monitored for side effect…

This study looks at teenagers aged 12 to 17 who have severe atopic dermatitis (eczema) with intense itching but only a mild to moderate rash. They are being treated with dupilumab (Dupixent), a standard medication. The goal is to see how well dupilumab controls itching, improves …

This study tests whether upadacitinib, an oral tablet, can help adults with moderate to severe eczema (atopic dermatitis) who didn't get enough relief from dupilumab injections. About 200 participants will be randomly assigned to take upadacitinib or continue dupilumab for 8 week…

This study is the first time REGN20423 is being tested in humans. It will enroll 144 adults, first healthy volunteers and then people with atopic dermatitis (eczema). The goal is to check safety, side effects, how the drug moves through the body, and whether it helps eczema sympt…

This study tests whether a drug called tralokinumab, given as a shot along with steroid cream, can safely control moderate-to-severe eczema in children aged 6 months to under 12 years. About 195 participants will receive either the drug or a placebo for 16 weeks, then all will ge…

This study tests a new medicine called galvokimig in 160 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if different doses can reduce skin redness, itching, and rash better than a placebo. Participants will receive injections and be monitored for 16…

This study tests a drug called FB825 in adults with moderate-to-severe atopic dermatitis (eczema). Participants receive five injections over 12 weeks, either FB825 or a placebo, to see if it improves skin symptoms like redness and itching. The goal is to find a new treatment opti…

This early-stage trial tests a new drug called TRB-061 in healthy adults and people with moderate-to-severe atopic dermatitis (eczema). The study checks for safety, side effects, and how the drug moves through the body. Participants receive either TRB-061 or a placebo as injectio…

This early-stage study tests a new drug called DCY636 for safety and tolerability in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The trial has two parts: a single dose in healthy adults and multiple doses in eczema patients. It aims to gather…

This study is testing a new biologic drug called Stapokibart, given as a shot, for adults with moderate-to-severe atopic dermatitis (eczema). The trial will enroll 1000 people to see if the drug is safe and helps control the condition. It is an open-label study, meaning everyone …

This study looks at the long-term safety and effectiveness of the drug afimkibart for people with atopic dermatitis (eczema) who have already taken it in earlier studies. About 120 adults will be followed to see how well the drug controls their eczema over time and what side effe…

This study tests an experimental drug called JNJ-95597528 in 180 adults with moderate to severe atopic dermatitis (eczema). Participants will receive either the drug or a placebo to see if it improves skin symptoms by at least 75% after 12 weeks. The goal is to control the diseas…

This study tests a new drug called remibrutinib (a tablet) against a placebo in 44 adults with chronic hives (either spontaneous or triggered by things like pressure or cold). The goal is to see if it reduces symptoms like itching and burning, and how it works in the body. Partic…

This study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema). About 280 participants will receive either the drug or a placebo to see if it reduces skin redness, thickness, and itching over 24 weeks. The goal is to find a saf…

This early-stage study tests a new drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The goal is to check safety and how the drug affects the body. Participants receive multiple doses and are monitored for side effect…

This study tests a bone marrow transplant from a family donor for children under 21 with severe non-cancer blood disorders like sickle cell disease, bone marrow failure, or immune problems. The goal is to see if the transplant can replace the diseased cells with healthy donor cel…

This study tests an experimental drug called BFB759, a lab-made antibody that blocks several inflammatory signals at once. Researchers want to see if it can reduce redness, swelling, and itching in adults with moderate-to-severe eczema that hasn't improved with creams. About 225 …

This study tests whether IMG-007 can safely reduce eczema symptoms like itching and redness in adults with moderate-to-severe disease who haven't responded well to topical treatments. About 405 participants will receive either the drug or a placebo, and researchers will measure s…

This early-stage trial tests whether a new drug called GS101 works like the approved eczema treatment Dupixent. Researchers will give a single shot to 294 healthy adults in China and compare how the drug moves through the body, its safety, and immune response. The goal is to see …

This study will follow about 1,000 adolescents and adults in China who are prescribed upadacitinib for moderate to severe atopic dermatitis (eczema). Researchers will track how patients use the medication, any dose changes, and how well they stick to their treatment over 12 month…

This study tests whether abrocitinib, a liquid medicine, can improve moderate-to-severe eczema in children aged 6 to 12. About 150 kids will be randomly assigned to receive either the drug or a placebo for 16 weeks. The goal is to see if the medicine clears the skin and reduces i…

This study is tracking 150 adults and teens with moderate-to-severe eczema who have already tried up to two biologic drugs without success. Researchers want to see how well the oral medication abrocitinib (Cibinqo) works in real-world settings. The main goals are to measure impro…

This study looks at whether children aged 1 to 17 with well-controlled atopic dermatitis (eczema) can safely reduce their dose or stop taking dupilumab (Dupixent) without their skin condition getting worse. About 30 children who have been on dupilumab for at least a year and have…

This study tests an experimental drug called SHR-1905 in 75 adults with moderate-to-severe atopic dermatitis (eczema). Half will get the drug, half a placebo, and neither they nor their doctors will know who got what. The main goal is to see if the drug can reduce eczema severity…

This 24-month study tests the long-term safety and effectiveness of abrocitinib, a liquid oral medication, in children aged 2 and older with moderate-to-severe atopic dermatitis (eczema). About 500 participants will receive the drug, with or without topical creams. The goal is to…

This study tests two medicines for children aged 2 to 12 with moderate to severe eczema that isn't controlled by creams. One group gets upadacitinib (a daily pill or liquid), the other gets dupilumab (an injection every 2 or 4 weeks). The goal is to see which better reduces skin …

This phase 3 trial tests an experimental drug called SHR-1819 in about 200 teenagers aged 12 to 17 with moderate-to-severe atopic dermatitis (eczema). Participants receive either the drug or a placebo injection. The study measures how well the drug clears skin rashes and reduces …

This study is tracking 1,000 adolescents and adults with moderate-to-severe atopic dermatitis (eczema) who are starting treatment with nemolizumab (Nemluvio®) in real-world clinics. The main goal is to see how well the drug controls skin symptoms and itching after 6 months, using…

This study tests a new drug called IBI356 in about 400 adults with moderate to severe atopic dermatitis (eczema). Participants receive either IBI356, dupilumab (an existing treatment), or a placebo by injection. The main goal is to see if IBI356 reduces eczema severity and itchin…

This study tests whether tralokinumab, an approved eczema drug, can improve moderate-to-severe atopic dermatitis in the genital area. About 30 adults will receive the drug and be monitored for 52 weeks using special skin imaging and symptom questionnaires. The goal is to see if i…

This study tests a daily pill called abrocitinib for people with Down syndrome who have eczema or a type of hair loss. About 56 participants will take the drug for up to 60 weeks to see if it safely controls their skin or scalp condition. The goal is to manage symptoms, not cure …

This study tests whether ZL-82 tablets can safely reduce eczema symptoms in adults with moderate to severe atopic dermatitis. About 111 participants will take either the drug or a placebo daily for 16 weeks, with regular checkups. The main goal is to see if ZL-82 improves skin se…

This program offers early access to upadacitinib (Rinvoq) for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis who have no other suitable treatments and cannot join ongoing clinical trials. A doctor must decide if the potential ben…

This early-stage trial tests a new drug called CKD-706, which is a biosimilar (a close copy) of the approved eczema treatment Dupixent. The study involves 519 healthy adults who will receive a single injection of either CKD-706, the US version of Dupixent, or the European version…

This pilot study is testing whether an oral medication called roflumilast (already used for other conditions) can help people aged 12 and older with moderate-to-severe atopic dermatitis (eczema). 36 participants will take a daily pill for 12 weeks. The study measures changes in e…

This early-stage trial is testing a new drug called ZL-1503 for safety and how the body processes it. It involves 84 participants: first healthy volunteers, then people with moderate to severe atopic dermatitis (eczema). The study is 'double-blind' and 'placebo-controlled,' meani…

This study is monitoring the safety and effectiveness of the prescription drug Cibinqo (abrocitinib) in people with moderate to severe atopic dermatitis (a type of eczema). About 1,100 participants in Korea will take the tablet as prescribed by their doctor and be observed for on…

This study is tracking 183 adults with moderate-to-severe atopic dermatitis (eczema) who are taking abrocitinib, a daily tablet. Researchers want to see how well the drug works in real-life settings, not just in controlled clinical trials. Participants will be followed for 24 mon…

This study looks at the long-term safety and effectiveness of a drug called CM512 for people with atopic dermatitis (eczema). It is for patients who have already finished a previous CM512 study. The main goal is to track any side effects over time.

This Phase 3 trial tests a drug called 611 in 180 Chinese teenagers (ages 12–17) with moderate-to-severe atopic dermatitis (eczema). 611 is an antibody that blocks a key driver of allergic inflammation. Participants receive injections every two weeks for up to a year. The main go…

This study tests whether adults with well-controlled eczema can safely extend the time between doses of the drug Dupilumab (Dupixent). 216 participants will be randomly assigned to receive the drug every 2, 3, or 4 weeks. Researchers will compare eczema severity and quality of li…

This study looks at whether CeraVe moisturizing cream can help maintain skin hydration and prevent eczema from coming back in people with mild to moderate atopic dermatitis. Participants first use a steroid cream to clear their skin, then apply either CeraVe or a standard emollie…

This early-stage trial tests an experimental injection called BxC-I17e, made from stem cell particles, in 45 adults with moderate to severe eczema (atopic dermatitis) who haven't responded well to standard creams. The main goal is to check safety and tolerability, with a small lo…

This Phase 3 trial tests an oral drug called ICP-332 for people with moderate to severe atopic dermatitis (eczema) who haven't gotten enough relief from topical treatments. About 552 adults will receive either the drug or a placebo pill for several weeks. Researchers will measure…

This study follows 200 people aged 12 and older with moderate-to-severe eczema who are starting a new prescription of abrocitinib. Researchers will track how much their skin improves over 12 months using standard eczema severity scores. The goal is to see how well the drug works …

This early-stage study tests a new imaging agent called 18F-4FN for PET scans to safely detect inflammation in the body. It involves 55 adults with cancer who are on immunotherapy or have suspected inflammation. The goal is to see if this agent can highlight areas of inflammation…

This study is testing a software tool called Belle.ai that uses artificial intelligence to help doctors diagnose common skin diseases. About 400 patients at dermatology clinics will have three photos taken of their skin condition. The AI will analyze the photos and suggest possib…

This study is testing whether giving healthy newborns a probiotic supplement (L. reuteri) can prevent colic and excessive crying. About 768 babies will receive either the probiotic or a placebo daily for the first 3 months. Researchers will track crying, fussiness, and stool patt…

This study tests whether a partially hydrolyzed formula with added synbiotics can prevent atopic dermatitis (eczema) in 400 infants at high risk for allergies. Babies are enrolled within 14 days of birth and followed for skin barrier function and eczema development. The goal is t…

This study is testing whether taking high-dose fish oil supplements during pregnancy can prevent asthma and persistent wheezing in early childhood. The trial will enroll 2000 pregnant Danish women with low blood levels of omega-3s. Participants take fish oil or placebo capsules d…

This study is testing whether taking a higher dose of vitamin D during pregnancy can prevent asthma and persistent wheezing in children up to age 3. Researchers will give 2000 pregnant women either vitamin D or a placebo daily from week 22-26 of pregnancy until one week after del…

This study tests whether a mobile app that provides psychological tools can improve quality of life for people with eczema, psoriasis, or chronic hives. Participants use the app over 32 weeks to learn coping strategies and wellness tips. The goal is to see if this digital approac…

This early-stage study tests a new drug called BBT001 in healthy volunteers and adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. About 198 participants will receive either BBT001 or a placebo, wit…

This study tests an ointment called HL-300 in people with mild-to-moderate atopic dermatitis (eczema). About 156 adults will apply the ointment or a placebo twice daily for 4 weeks. Researchers will check if the ointment reduces eczema severity and improves symptoms.

This study tests if a spray made from ground cardamom seeds and a harmless skin bacteria (Roseomonas mucosa) can improve eczema symptoms in people aged 2 and older. Participants apply the spray 2-3 times a week for 14 weeks and are monitored remotely for about 7 months. Half rece…

This study tests a cream called tapinarof on babies and toddlers aged 3 to 23 months with eczema (atopic dermatitis). The goal is to see if it can clear or nearly clear their skin rash. About 180 children will take part, and the cream is compared to a placebo (inactive cream) for…

This study tests whether a new oral drug called ENV-294 can safely reduce eczema severity in adults with moderate-to-severe atopic dermatitis. Sixty participants will take either ENV-294 or a placebo pill daily for 12 weeks. Researchers will measure changes in skin symptoms and t…

This study compares the standard dose of cetirizine (10 mg daily) to a higher dose (40 mg daily) for treating acute hives in adults. Researchers want to see if the higher dose relieves symptoms faster and reduces the need for steroid rescue medication. Participants take the assig…

This study tests an experimental daily tablet (PF-08049820) for adults with moderate to severe eczema (atopic dermatitis). About 165 participants will take either the study drug or a placebo for 12 weeks. Researchers will check skin improvement, itching, and safety through clinic…

This early-stage trial is testing a new injectable drug called ARQ-234 in healthy volunteers and people with moderate to severe eczema. The main goals are to check safety and how the body processes the drug, while also looking for early signs that it might improve eczema symptoms…

This Phase 2 study tests an experimental ointment called GX-03 in adults with moderate-to-severe eczema. About 110 to 200 participants will apply either the active ointment or a placebo for 8 weeks. Researchers will measure improvements in skin rash, itch, and patient-reported sy…

This study tracks 184 people with moderate-to-severe atopic dermatitis (eczema) who are already starting dupilumab treatment. Over six months, researchers will measure changes in anxiety, depression, and quality of life using standard questionnaires. The goal is to see if treatin…

This study tests whether a daily probiotic supplement called BioAmicus Complete can help infants with colic, constipation, diarrhea, and eczema. 140 babies will receive either the probiotic drops or a placebo (sunflower oil) for 25 days. Researchers will track changes in stool, c…

This study tests whether a special silk dressing (SYLKE®) causes fewer skin problems like rashes, blisters, or redness compared to standard skin glue (Dermabond®) after ACL knee surgery. About 100 people aged 14 to 60 having ACL reconstruction will be randomly assigned to one of …

This early-stage study tests a new medicine called SKB575 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goals are to check safety and how the body processes the drug. A small group of eczema patients will also be monitored for skin …

This study tests whether a daily probiotic drink can improve immune function and reduce skin inflammation in women aged 40-60 going through menopause. Participants will drink either a probiotic or a plain milk drink for 8 weeks. Researchers will measure immune aging, inflammation…

This study tests two experimental injectable drugs (PF-07275315 and PF-07264660) for adults with moderate to severe atopic dermatitis (eczema) that hasn't improved with skin creams. About 340 participants will receive the drugs or a placebo over up to 13 months to see if the medi…

This study is testing a cream called RV4421B-EV0407, a medical device already sold in some countries, for mild to moderate atopic dermatitis (eczema). It includes 105 participants from 3 months old to adults, with diverse skin types. The cream is used alone or with steroid creams…

This early-stage study tests a new oral drug called SYX-5219 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. About 149 participants will take single or multiple doses ov…

This study tests whether dupilumab (Dupixent) can improve sleep and reduce itching in 40 children aged 6-17 with moderate to severe eczema. Participants receive dupilumab for 12 weeks, and researchers measure sleep quality and itch using questionnaires and overnight sleep tests. …

This study looks at the safety of a nasal spray called neffy compared to a standard epinephrine shot for treating allergic reactions. It involves 600 people aged 4 and older who have an allergic reaction during a food challenge or allergy shot session. The goal is to see if the s…

This study compares black seed (Nigella sativa) oil to standard steroid ear drops for treating eczema in the ear canal. 85 adults with ear eczema will use either the oil or steroid drops twice daily for 10 days. Researchers will measure changes in inflammation, itching, and pain …

This early-stage study tests an experimental drug called PF-07832837 in healthy adults and people with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. Researchers will also look for early signs that the drug…

This study tests an experimental drug called SM17, given as a shot under the skin, for adults with moderate-to-severe eczema (atopic dermatitis). The goal is to see if it safely reduces skin redness, swelling, and itching. About 200 participants will receive either SM17 or a plac…

This study tests whether a diet low in saturated fats and rich in whole grains, fruits, and vegetables can reduce the severity of atopic dermatitis (eczema) in young adults. Researchers will track changes in skin symptoms and barrier function over two months. The goal is to see i…

This study tests a moisturizing lotion made with Edelweiss extract, macadamia oil, and shea butter in 15 adults with mild-to-moderate eczema. Over 4 weeks, doctors will check skin redness, dryness, and severity, and participants will report any side effects. The goal is to see if…

This study tests a daily pill called soquelitinib in 200 adults with moderate to severe atopic dermatitis (eczema). Participants take either the drug or a placebo for 12 weeks, and doctors track skin improvements and side effects. The goal is to see if soquelitinib can safely red…

This study tests an experimental drug called IBI3002 in 120 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, thickness, and itching better than a placebo over 16 weeks. Participants will be randomly assigned to receive eith…

This study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…

This study is testing a new laser called PALLAS to treat skin diseases like vitiligo, psoriasis, alopecia areata, and atopic dermatitis. About 50 people will receive UVB laser treatments twice a week for up to 3 months. The goal is to see if the laser improves the skin condition …

This Phase 2 trial is testing an experimental drug called GHZ339 in 224 adults with moderate to severe atopic dermatitis (eczema). Participants will receive either the drug or a placebo, and researchers will measure changes in eczema severity using the EASI score at 16 weeks. The…

This early-stage study tests an experimental oral drug, LPX-TI641, in 48 adults with atopic dermatitis (eczema) or psoriasis. The main goal is to check if the drug is safe and tolerable compared to a placebo over 28 days. Researchers will also measure how the drug moves through t…

This pilot study tests whether a cream made with glycomacropeptide, a milk protein, can reduce eczema symptoms in children aged 2 to 12 with mild atopic dermatitis. Twenty children will apply either the glycomacropeptide cream or a standard moisturizer twice daily for four weeks.…

This early-stage study tests a new drug called BBT001 in healthy volunteers and adults with moderate-to-severe eczema (atopic dermatitis). The main goal is to check safety and how the body processes the drug. About 63 participants will receive either the drug or a placebo, with d…

This study tests a new cream made with ceramide, coconut oil, and cholesterol to see if it improves skin hydration, redness, and itch in people with mild skin barrier problems like eczema, psoriasis, or dry skin. 26 adults will apply either the new cream or plain petrolatum twice…

This pilot study tests whether hypnosis can help children aged 8 to 17 with atopic dermatitis (eczema). The experimental group will learn a 'superhero costume' hypnosis technique and practice self-hypnosis at home. The study only aims to see if a larger trial is possible, not to …

This study examines how common eczema treatments, including antibiotics and bleach baths, change the types and amounts of bacteria on the skin. Researchers will compare people with eczema to healthy volunteers. The goal is to understand the skin microbiome better, not to test a n…

This study aims to learn more about how diseases related to blood clots, the immune system, and blood vessels start and change over time. Researchers will enroll up to 1,000 people aged 5 and older, including those with these conditions, their healthy relatives, and healthy volun…

This study looks at the causes and effects of food allergies and related conditions like eczema and eosinophilic esophagitis. Researchers will collect blood, skin, and genetic samples from up to 1,800 people over many years. The goal is to find biomarkers and pathways that explai…

This observational registry will follow 1,500 adolescents aged 12–15 with moderate-to-severe atopic dermatitis (eczema) across North America and Europe. Researchers aim to document the disease's natural history, how it's managed, and long-term outcomes. Participants will be under…

This study looks at 200 people aged 3–21 with eczema and high IgE levels who may have milk or peanut allergies. Researchers will use oral food challenges to find better ways to predict true allergies. The goal is to make allergy tests more accurate and reduce unnecessary food res…

This study is a registry that will follow 1,000 adults and teens with atopic dermatitis (eczema) who are starting or switching systemic treatments. Researchers will track which treatments people use, how long they take them, and why they change or stop. The goal is to better unde…

This study looks at the tiny organisms living on our skin—like bacteria and fungi—and how they might differ in people with eczema (atopic dermatitis). Researchers will collect skin samples from healthy volunteers and patients aged 2 to 40 with moderate to severe eczema, as well a…

This international study observes how people with atopic dermatitis (eczema) access healthcare, what treatments they receive, and how the disease affects their daily lives. Researchers will collect data from routine medical records of about 9,600 participants across multiple coun…

This study looks for better ways to detect lung inflammation and infections early in people who have received a stem cell transplant from a donor. About 40 participants aged 5 to 70 will get regular lung scans, breathing tests, blood draws, and a procedure where a tube collects f…

This study is collecting skin and blood samples from 830 people with chronic inflammatory skin diseases like psoriasis, eczema, and lupus. Researchers want to find biological markers that can predict how well a person will respond to treatment after one year. The goal is to move …

This study is testing a handheld device called Nevisense Go to see if it can predict eczema (atopic dermatitis) flares before they become visible or cause symptoms. About 450 people aged 12 to 89 with a history of eczema flares will use the device at home for 90 days. The goal is…

This study looks at whether tiny DNA fragments released from damaged skin cells into the blood can help measure eczema severity. Researchers will compare blood and skin samples from 80 adults with eczema and healthy volunteers. The goal is to understand how these DNA fragments tr…

This study looks at how dupilumab, an approved eczema drug, changes immune cells in the skin. Researchers will take skin samples from 15 adults with moderate-to-severe eczema before and after treatment. The goal is to understand the molecular changes that lead to improvement, not…

This study looks at a condition called alloknesia, where light touch—like from clothing or a breeze—triggers itching. Researchers want to find out how common this is in people with atopic dermatitis (eczema) and how it affects their daily lives. About 160 adults with eczema will …

This study aims to understand how the immune system and skin healing are connected in people with primary immunodeficiency, psoriasis, or eczema, as well as in healthy volunteers. Researchers will collect skin biopsies, blood samples, and optional skin swabs to analyze microbes a…

This study collects biological samples—like blood, skin biopsies, and swabs—from people with or at risk for skin diseases, as well as healthy volunteers. Researchers will use these samples to study the causes of skin conditions and explore potential treatments. Up to 700 particip…

This study will follow 600 adults with moderate-to-severe atopic dermatitis (eczema) who are eligible for or already taking systemic medications. Researchers will track which treatments are used, how long patients stay on them, and how well they follow their regimen. The goal is …

This study looks at whether a specific genetic change (IL-4Ra R576) is linked to more severe eczema. Researchers will measure skin symptoms, immune markers, and skin bacteria in 111 people aged 6 to 65 with atopic dermatitis. No new treatment is being tested; the goal is to bette…

This study tests whether a special microscope (reflectance confocal microscopy) can detect skin changes in people with moderate-to-severe eczema who are taking tralokinumab. The drug blocks a protein involved in inflammation and is already known to help eczema. Researchers want t…

This pilot study is testing whether Botox injections can change how skin cells behave in people with mild-to-moderate eczema. Eight adults will receive small doses of Botox into their eczema patches. Researchers will measure changes in eczema severity and analyze skin biopsies to…

This study is building a large database and biobank from 2200 people with chronic inflammatory diseases like lupus, multiple sclerosis, severe asthma, and psoriasis. Researchers will collect blood samples and track disease activity over time using standard medical scores. The goa…

This study looks at the bacteria living on the skin of people with cutaneous T cell lymphoma, a rare type of skin cancer. Researchers will compare these bacteria to those on healthy people and people with other skin conditions like psoriasis. The goal is to understand if certain …

This study examines how germs living on and in the body, along with environmental factors like pollution, may influence allergic diseases such as asthma and eczema in people living in Mali. Researchers will collect samples and health information from 288 participants, both with a…

This study aims to better understand chronic hand eczema and atopic dermatitis by using gentle skin tape strips and imaging to analyze skin changes and genetic activity. Researchers will compare people with these skin conditions to healthy volunteers. The goal is to identify what…

This study is creating a database of children and young adults with eczema who have used or will start systemic (whole-body) treatments. Researchers will track how well these treatments work using doctor and patient reports. The goal is to make it easier to recruit for future stu…

This study collects skin samples from 500 people with conditions like acne, eczema, and psoriasis, as well as healthy volunteers. Researchers will analyze the samples to find biomarkers and gene patterns linked to inflammation. The goal is to better understand these skin diseases…

This study is testing a tool called B-COMPASS that uses a 22-question survey to predict whether people will follow their prescribed treatments. Researchers will enroll 3100 adults with cardiovascular, endocrine, immune, nerve, cancer, or rare diseases across Europe. The goal is t…

This study looks at how high-frequency 5G waves (27.5 GHz) affect the skin. Researchers will expose healthy volunteers and people with certain skin conditions to these waves and analyze skin cell changes using advanced techniques. The goal is to understand any biological effects,…

This pilot study is measuring prednisolone levels in 120 people with inflammatory diseases like thyroid eye disease, vasculitis, COPD, asthma, and others. Participants take high-dose prednisolone as part of their routine care, and researchers take timed blood samples to see how t…

This study aims to create a large collection of blood samples and medical information from 800 people with autoimmune or inflammatory skin diseases. Researchers will use these samples to find new biomarkers and better understand what causes these conditions. The goal is to help d…

Stanford University is recruiting 2,500 people with possible allergies to improve how allergies are diagnosed. Researchers will study skin test responses and look at genetic and immune system factors. This study does not test any new treatment, but aims to deepen knowledge of all…

This study is testing a new method to measure allergy-related substances (IgE) in blood and urine. Researchers want to see if this new technique works as well as current tests. About 1,376 children and adults with allergies will provide blood and urine samples during routine visi…

This study is collecting blood, urine, and breath samples from 280 adults—including those with metal allergies and healthy volunteers—to see if exposure to heavy metals and pollutants leaves distinct biological markers. Researchers will compare levels of metals, lung function, an…

This study looks at 320 adults who are about to start strong immune-suppressing therapy and have already had at least two COVID-19 shots. Researchers want to find out if giving a COVID-19 booster right before starting therapy or waiting six months provides better protection. Part…

This study enrolls 250 infants born by C-section to see if personalized diet and probiotic advice can improve their gut bacteria and reduce early signs of eczema. Babies provide stool samples over two years, and parents get tailored recommendations based on their baby's microbiom…

This study is creating a large registry of 800 people receiving biologic medications for immune conditions like autoimmune diseases and primary immune deficiencies. Researchers will collect blood samples and health data to better understand how these treatments work and who respo…

This study follows 900 people aged 6 and older with atopic dermatitis (eczema) who are taking dupilumab as part of their normal care. Researchers will track symptoms, quality of life, and disease control over two years using questionnaires and checkups. The goal is to see how wel…

This study looks at how indoor air and dust pollutants in classrooms impact children's allergies and lung function. Researchers will monitor 100 children, comparing those with allergies to those without, using questionnaires, allergy tests, and breathing tests. The goal is to ide…

This long-term study follows 1,000 people with eczema and related allergies, plus healthy volunteers, to see what factors help the disease go into remission. Researchers will collect medical and lifestyle data to find patterns and possible biomarkers. The goal is to better unders…

This study aims to find the genetic causes behind certain allergic and immune system disorders. Researchers will collect blood, saliva, and tissue samples from up to 10,000 people of all ages, along with some family members. No treatments are given; the goal is simply to learn mo…

This study looks at whether babies born with certain self-reactive antibodies are more likely to develop eczema. Researchers will test umbilical cord blood from 500 newborns—some with a family history of allergies or eczema, some without—and follow them for two years. The goal is…

This study collects blood, urine, and skin samples from 200 adults with cutaneous T-cell lymphoma, eczema, or atopic dermatitis. The samples are stored and used for current and future research, such as studying proteins in the blood and tissue. Participants must have one of these…

This study aims to find out how often adults with atopic dermatitis (eczema) have eyelid involvement. Researchers will examine 550 patients from two French hospitals using skin exams, allergy tests, and eye check-ups. The goal is to better understand this common but poorly studie…

This study aims to understand why many people with atopic dermatitis (eczema) don't use their topical medication as prescribed, which can lead to worse symptoms and higher healthcare costs. About 30 adults and children with active dermatitis will be divided into groups to receive…

This study looks at how skin conditions related to cancer or cancer treatments affect the well-being of cancer patients and survivors. About 1,025 participants will fill out questionnaires about their skin condition. The goal is to better understand these effects and improve trea…

This study follows 400 pregnant women with eczema to see if the drug abrocitinib (CIBINQO) is safe during pregnancy. Half the women take the drug, the other half do not. Researchers track birth defects and infant health up to 12 months after birth. No extra doctor visits are need…

This study will analyze health records of over 5,600 pregnant women with atopic dermatitis (eczema) to compare infant outcomes between those who used ruxolitinib cream (Opzelura) and those who used topical corticosteroid creams. Researchers will look at rates of major birth defec…

This study follows about 958 pregnant women with mild to moderate eczema (atopic dermatitis) who use ruxolitinib cream (Opzelura) and compares them to similar women who do not use the cream. Researchers track birth defects and other pregnancy outcomes to see if the cream is linke…

This study aims to collect blood, nasal fluid, skin cells, urine, and medical data from 10,000 people aged 3 to 100 with allergies, asthma, eczema, or sinus issues. Participants will have up to 3 years of follow-up visits and questionnaires. The goal is to create a large reposito…

This study collects blood and skin samples from 200 people with eczema, food allergies, or neither. Researchers will analyze these samples to find shared genetic or biochemical signals. The goal is to better understand how these conditions are connected, which could lead to bette…

This study looks at how the eczema drug dupilumab works in people of different ethnic backgrounds. Researchers want to understand why Asian and African American people get eczema more often and respond differently to treatment. The study will compare 30 adults with moderate-to-se…